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All coffee types decrease the risk of
adverse clinical outcomes in chronic liver
disease: a UK Biobank study
Oliver J. Kennedy1* , Jonathan A. Fallowfield2, Robin Poole1, Peter C. Hayes2, Julie Parkes1 and Paul J. Roderick1
Abstract
Background: Chronic liver disease (CLD) is a growing cause of morbidity and mortality worldwide, particularly in
low to middle-income countries with high disease burden and limited treatment availability. Coffee consumption
has been linked with lower rates of CLD, but little is known about the effects of different coffee types, which vary in
chemical composition. This study aimed to investigate associations of coffee consumption, including decaffeinated,
instant and ground coffee, with chronic liver disease outcomes.
Methods: A total of 494,585 UK Biobank participants with known coffee consumption and electronic linkage to
hospital, death and cancer records were included in this study. Cox regression was used to estimate hazard ratios
(HR) of incident CLD, incident CLD or steatosis, incident hepatocellular carcinoma (HCC) and death from CLD
according to coffee consumption of any type as well as for decaffeinated, instant and ground coffee individually.
Results: Among 384,818 coffee drinkers and 109,767 non-coffee drinkers, there were 3600 cases of CLD, 5439 cases
of CLD or steatosis, 184 cases of HCC and 301 deaths from CLD during a median follow-up of 10.7 years. Compared
to non-coffee drinkers, coffee drinkers had lower adjusted HRs of CLD (HR 0.79, 95% CI 0.72–0.86), CLD or steatosis
(HR 0.80, 95% CI 0.75–0.86), death from CLD (HR 0.51, 95% CI 0.39–0.67) and HCC (HR 0.80, 95% CI 0.54–1.19). The
associations for decaffeinated, instant and ground coffee individually were similar to all types combined.
Conclusion: The finding that all types of coffee are protective against CLD is significant given the increasing
incidence of CLD worldwide and the potential of coffee as an intervention to prevent CLD onset or progression.
Keywords: Coffee, Chronic liver disease, Cirrhosis, Hepatocellular carcinoma
Background
Chronic liver disease (CLD) is a major health problem
worldwide. Between 1990 and 2017, global deaths due
to CLD increased from 899,000 (1.9% of total) to 1.32
million (2.4% of total) [1]. During the same period,
disability-adjusted life-years lost to CLD increased
from 30.5 million to 41.4 million. The burden of CLD
is highest in low to middle-income countries where
treatment options are also limited. Sub-Saharan Africa
is the region that is most affected followed by Central
and South America, Eastern Europe and Southeast
Asia [1, 2]. The commonest aetiologies of CLD are
alcohol-related liver disease (ALD), chronic hepatitis
B and C infection, and non-alcoholic fatty liver dis-
ease (NAFLD) [3]. These conditions involve destruc-
tion and regeneration of liver parenchyma leading to
liver fibrosis and then cirrhosis. Cirrhosis can be fatal
due to complications related to portal hypertension,
liver failure or the development of hepatocellular car-
cinoma (HCC).
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Coffee is a popular beverage in most societies [4]. It
comprises hundreds of chemical compounds, some of
which are thought to have in vivo properties, including
caffeine, chlorogenic acid, kahweol and cafestol [5]. Ob-
servational and laboratory studies suggest that consump-
tion of coffee confers a protective effect against CLD,
including cirrhosis and HCC [6–8]. This effect has been
observed among drinkers of caffeinated and, to a lesser
extent, decaffeinated coffee [9]. Based on these observa-
tions, coffee has been proposed as a potential interven-
tion to prevent CLD onset and progression or HCC in
at-risk patients [7]. However, the attributes of an effect-
ive coffee-based intervention remain uncertain in terms
of quantity and preparation, which substantially affects
composition (e.g. decaffeinated coffee lacks caffeine,
while filtered and instant coffee have only minimal
amounts of kahweol and cafestol) [10]. The aim of this
study was to investigate associations of coffee consump-
tion, including the effects of different coffee types (and,
thus, composition), with CLD outcomes in a large pro-
spective cohort.
Methods
Study population and baseline assessment
UK Biobank is a prospective longitudinal study aimed at
identifying genetic and behavioural determinants of
health outcomes. A protocol for the study is available
online [11]. Prospective participants were identified from
National Health Service registers, which include most of
the UK population. However, invitations were mostly
sent to people within 10miles of the ~ 22 UK Biobank
assessment centres, which were in urban areas. Around
5 million invitations were sent with 500,000 men and
women aged 40–69 between 2006 and 2010 agreeing to
participate. All participants attended an assessment
centre, where they answered questions about medical
history and lifestyle, underwent physical examination,
and gave urine and blood samples.
Baseline coffee consumption was ascertained by a
touchscreen questionnaire. Participants were asked how
many cups of coffee they drank each day. Responses of
> 10 required confirmation and > 99 were rejected. Cof-
fee drinkers were asked what type of coffee they usually
drank from “decaffeinated”, “instant”, “ground (including
espresso)” or “other”. Participants were also asked
whether they had been told by a doctor that they had
diabetes and whether they currently or previously
smoked tobacco. The response rates to these questions
were > 99%.
Participants were asked how frequently they consumed
alcohol (number of days each week or month) and about
weekly / monthly quantities of alcohol types (e.g. spirits,
red / white wine, beer, cider etc.). To standardise re-
sponses, the questionnaire specified portion sizes for
each type of alcohol (e.g. “there are six glasses in an
average bottle [of wine]”). After extracting the data from
UK Biobank, weekly “units” (one unit is equivalent to 10
mL of pure ethanol) were calculated for each participant
using the specified portion sizes and assumed alcohol
content, as shown in supplementary Table 1. While 99%
of participants stated their frequency of alcohol con-
sumption, only 83.7% stated quantities that enabled esti-
mation of total weekly units. The baseline characteristics
of participants according to whether weekly units could
be estimated are shown in supplementary Table 2, with
participants without weekly units more likely to be fe-
male, deprived, non-smokers, consume less coffee, have
diabetes, and drink alcohol less than once a week (i.e.
“special occasions only” or “one to three times a
month”). Participants without unit data had marginally
higher rates of incident CLD (0.8% vs. 0.7%) and inci-
dent CLD or steatosis (1.3% vs. 1.1%), a marginally lower
rate of death from CLD (0.045% vs 0.064%), and a simi-
lar rate of incident HCC (0.037% vs. 0.037%).
Participants’ body mass indices (BMI) were calculated
from height and weight measured by trained nurses dur-
ing the initial assessment centre visit. For these measure-
ments, participants removed shoes and heavy clothing.
Height was measured to the nearest centimetre and
weight to the nearest 0.5 kg.
UK Biobank assigned a Townsend deprivation score to
each participant based on postcode of habitation. Town-
send deprivation scores are calculated from levels of em-
ployment, home and car ownership and household
overcrowding in a given area [12]. The median Town-
send deprivation score was − 2.1, which is less deprived
than the UK average of − 0.35 and comparable to the
25th percentile of UK deprivation of − 2.35 [13].
All UK Biobank participants gave consent for contin-
ued follow-up by linkage to electronic health records.
These included death records and cancer registers,
which are maintained by the Office for National Statis-
tics and the Registrar General’s Office, and hospital re-
cords, which are held by the Department of Health’s
Hospital Episode Statistics and the Scottish Morbidity
Record. Ethics approval was given by North West Multi-
Centre Research Ethics Committee.
Inclusion and exclusion criteria
The UK Biobank dataset used in this study included 502,
528 participants. Participants were excluded who with-
drew consent (n = 22) or had a baseline medical condi-
tion that likely represented CLD (n = 5691). Baseline
conditions were identified from hospital and cancer re-
cords and from interviews during the baseline assess-
ment centre visit. Lists of ICD (International
Classification of Diseases) codes and conditions from the
baseline interview used to exclude participants are
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shown in supplementary Tables 3a-c. Participants were
also excluded if they did not provide baseline coffee con-
sumption (n = 2230, 0.44% of total). Supplementary
Table 4 shows that these participants were more likely
to be male, of non-white ethnicity (58.7% vs. 5.4%), de-
prived and have diabetes, but less likely to drink alcohol
or smoke compared to the participants who did provide
baseline coffee consumption. After the exclusions, there
were 494,585 participants (~ 98% of total) available for
inclusion in this study (the exact numbers used in each
analysis are specified below).
Outcome ascertainment
The main outcomes were incident CLD, incident HCC
and death from CLD. The term “CLD” was taken to in-
clude chronic liver diseases involving underlying de-
struction of liver parenchyma and fibrosis. This included
HCC, which was also analysed as a separate outcome.
However, CLD did not include simple fatty liver disease
(i.e. isolated steatosis without inflammation). The effect
of not including steatosis was examined by analysing a
fourth outcome of “incident CLD or steatosis”.
The outcomes of incident CLD, incident CLD or
steatosis and HCC were identified from hospital re-
cords, cancer registers and the primary or secondary
causes on death records using the linked datasets de-
scribed above. The outcome of death from CLD was
identified from the primary causes on death records.
The ICD-9 and ICD-10 codes used to identify cases
are shown in Table 1.
Statistical analyses
Cox proportional hazard regression was used to estimate
age and sex adjusted associations of confounding vari-
ables with incident CLD and death from CLD. Non-
cases were right censored at the date of loss to follow-
up, date of non-CLD death or the end of follow-up. The
date of loss to follow-up was recorded by UK Biobank
and based on when it stopped receiving follow-up data
for a participant. The end of follow-up was the date of
data extraction (November 2019). The confounding vari-
ables considered were based on previous similar studies,
known risk factors for CLD and informed using causal
directed acyclic graphs [7, 14]. These were Townsend
deprivation, smoking status (never, current or previous),
diabetes (yes or no), BMI, ethnicity (white or other eth-
nicity), alcohol frequency (less than weekly, once or
twice a week, three or four times a week, and daily or al-
most daily) and weekly alcohol units.
Cox proportional hazard regression was used to esti-
mate unadjusted and adjusted hazard ratios (HRs) with
95% confidence intervals (CI) for each outcome accord-
ing to consumption of coffee of all types combined as
well as for decaffeinated, instant and ground (including
espresso) coffee separately. Non-drinkers of coffee were
used as the reference group in all analyses. HRs of each
outcome were calculated according to any amount of
coffee compared to none as well as for 0.5, 1, 2, 3, 4
and ≥ 5 cups each day compared to none.
For the adjusted analyses, which are described in fur-
ther detail below, it was necessary to determine if the
confounding variables that were continuous (i.e. age,
BMI, deprivation and weekly alcohol units) were linearly
or non-linearly associated with the outcomes. For this
purpose, univariate Cox hazard regression was per-
formed using penalised splines [15]. Where the associa-
tions were non-linear, as determined by a Wald-type test
using the nonlinear coefficient estimates [16], flexible
splines were used in further analyses. Otherwise, linear
terms were used. This approach is similar to previous
studies that have modelled continuous variables [15].
Adjusted HRs were calculated using three different
Cox models. The first model included covariates for age
and sex only. The second additionally included covari-
ates for Townsend deprivation, smoking status, diabetes,
ethnicity, alcohol frequency and BMI. The third model
was the same as the second but included weekly alcohol
units instead of alcohol frequency. All the analyses were
performed with complete cases, which equated to 494,
585 (100% of total), 494,585 (100%), 486,251 (98.3%) and
408,835 (82.6%) participants, respectively, in the un-
adjusted and three adjusted models described above.
Potential violations of the proportional hazards (PH)
assumption were investigated by examining, for each
variable, correlations between scaled Schoenfeld resid-
uals and time. Where there was an indication of a viola-
tion, log(−log) and cumulative incidence plots were
constructed and visually inspected, and sensitivity ana-
lyses were performed that involved stratification on the
variable of interest. Stratification accounts for violation
Table 1 ICD-9 and ICD-10 codes used to identify outcomes in hospital records, cancer registers and death records
ICD-9 ICD-10
CLD 1550, 4560–4562, 5710, 5712–5714, 57,150–57,152, 57,
158, 57,159, 5718, 5719, 5723, 5724, 5728, 7895
C22.0, K70.0-K70.4, K70.9, K72.1, K72.9, K73.0-K73.2, K73.8, K73.9, K74.0-K74.2,
K74.6, K75.8, K75.9, K76.6, K76.7, R18, I85.0, I85.9, I86.4, I98.2, I98.3
Steatosis 5718 K76.0
HCC 1550 C22.0
Abbreviations: ICD-9 International Classification of Diseases 9th Revision), ICD-10 (International Classification of Diseases 10th Revision), CLD (chronic liver disease),
HCC (hepatocellular carcinoma)
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of the PH assumption by allowing a different baseline
hazard in each strata.
To investigate possible reverse causation, HRs were
calculated for each outcome according to coffee con-
sumption after removing all cases occurring within the
first 5 years from recruitment. Finally, subgroup analyses
were performed by calculating adjusted HRs of CLD in
each BMI category (i.e. < 25, 25–29, ≥30 kg/m2) and in
participants with and without diabetes. All analyses were
performed in R (Version 4.0.3). The Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) guidelines [17] were followed in reporting
this study.
Patient involvement
This work was informed by the results of a patient and
public involvement focus group and survey of patients
with CLD. This demonstrated a high level of interest
among patients in potential randomised controlled trials
evaluating coffee as an intervention in CLD.
Results
A total of 494,585 participants with known baseline cof-
fee consumption and without baseline CLD were
followed-up for a median of 10.7 years (interquartile
range: 1.4 years). During the follow-up, there were 3600
cases of incident CLD, 5439 cases of incident CLD or
steatosis, 184 cases of incident HCC (including 83
deaths) and 301 deaths from CLD (Fig. 1).
There were 384,818 (78%) coffee drinkers (all types
combined), with a median consumption of 2 cups each
day (interquartile range = 3 cups each day), in addition
to 109,767 (22%) non-coffee drinkers. Non-coffee
drinkers were more likely to be non-smokers and
Fig. 1 A flow diagram showing the derivation of the cohort used in this study and the sources for identification of cases for each outcome
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teetotal but were more deprived and had a higher preva-
lence of diabetes and obesity (Table 2). Coffee drinkers
in the highest category of consumption (i.e. ≥5 cups each
day) were most likely to be male, overweight and smoke.
Of coffee drinkers, 73,644 (19%), 212,586 (55%) and
86,987 (23%), respectively, were drinkers of decaffein-
ated, instant and ground (including espresso) coffee. The
baseline characteristics of these participants are shown
in supplementary Tables 5, 6, 7, 8. Decaffeinated coffee
drinkers were more likely to be female (63.1% vs. 50.5%
for instant and 51.7% for ground), older (median age at
baseline 59 vs. 58 and 57) and less likely to be current
smokers (6.7% vs 12.6 and 9.2%). Drinkers of ground
coffee had the highest median weekly alcohol consump-
tion (20.2 units vs. 17.2 for instant and 12.8 for decaf-
feinated) and were least likely to have diabetes (3.9% vs.
5.4 and 5.0%).
Townsend deprivation quartile, previous or current
smoking, diabetes and BMI were associated with in-
creased risk of incident CLD and death from CLD, as
shown in supplementary Table 9. The highest quartile of
weekly alcohol units and daily or almost daily alcohol
consumption were also associated with increased risk
but not the lower categories. There was no association
of ethnicity with incident CLD or death from CLD. The
results of the univariate Cox analyses using penalised
splines are shown in in supplementary Figs. 1, 2, 3, 4.
The tests for non-linearity were significant for BMI (p-
value < 0.001) and weekly alcohol units (p-value < 0.001)
but not for age (p-value 0.74) or deprivation (p-value
0.19). Thus, these continuous covariates were modelled
in the main analysis using splines for BMI and weekly al-
cohol units and linear terms for age and deprivation.
Coffee drinkers (all types combined) had lower fully
adjusted risks than non-coffee drinkers of incident CLD
(HR 0.79, 95% CI 0.72–0.86), incident CLD or steatosis
(HR 0.80, 95% CI 0.75–0.86), and death from CLD (HR
0.51, 95% CI 0.39–0.67) (Table 3 and Fig. 2). There was
a similar, though less statistically significant, association
between coffee consumption and incident HCC (HR 0.80,
95% CI 0.54–1.19). The reductions in HRs were propor-
tional to the quantity of coffee consumption up to around
3–4 cups each day beyond which further increases in con-
sumption provided no additional benefit. The adjusted
HRs were very similar though slightly larger in magnitude
compared to the unadjusted HRs. After excluding cases
occurring within the first 5 years, coffee drinkers still had
lower fully adjusted risks than non-coffee drinkers of inci-
dent CLD (HR 0.79, 95% CI 0.70–0.90), incident CLD or
steatosis (HR 0.79, 95% CI 0.71–0.88) and death from
CLD (HR 0.56, 95% CI 0.39–0.78).
Schoenfeld residuals from the fully adjusted Cox
model indicated that smoking status did not meet the
PH assumption (p-value 0.02). Log(−log) and cumulative
incidence plots, which are shown in supplementary
Figs. 5 and 6 respectively, suggested that there was a
period around 200 days when the hazard among current
smokers was lower than expected, though this quickly
self-corrected thereafter. When the Cox model was
stratified on smoking, which accounts for violation in
the PH assumption, the estimates for the association be-
tween coffee and incident CLD were the same as the un-
stratified analysis (i.e. HR 0.79, 95% CI 0.72–0.86). In
addition, the Schoenfeld residuals did not show any evi-
dence of violation when smoking status was re-
categorised as smokers vs. non-smokers, and when this
was used in the fully adjusted Cox model the association
of coffee consumption with CLD was essentially un-
changed. As such, the effect of any violation in the PH
assumption on the estimates was negligible.
HRs of incident CLD, incident CLD or steatosis, inci-
dent HCC and death from CLD according to consump-
tion of decaffeinated, instant and ground (including
espresso) coffee are shown in Tables 4, 5, 6 and Fig. 2.
For consumption of each coffee type, there were strong
inverse associations with incident CLD, incident CLD or
steatosis and death from CLD, though precision was
lower due to smaller sample sizes. The associations were
similar after excluding cases occurring in the first 5 years
of follow-up. There was a weaker inverse association of
all coffee types with HCC that did not reach significance
in the fully adjusted models. The inverse associations be-
tween coffee and CLD were similar in the normal, over-
weight and obese BMI categories and in participants
with and without diabetes (supplementary Table 10).
Discussion
This cohort study investigated associations of coffee
consumption with incident CLD, incident CLD or stea-
tosis, incident HCC and death from CLD among nearly
half a million participants, of whom 78% were regular
coffee drinkers (median consumption of two cups each
day). During a median follow-up of 10.7 years, there
were 3600 cases of incident CLD, 5439 cases of incident
CLD or steatosis, 184 cases of incident HCC and 301
deaths from CLD. Compared to non-coffee drinkers,
coffee drinkers (all types and amounts combined) had
21, 20 and 49% reduced risks of incident CLD, incident
CLD or steatosis and death from CLD, respectively. The
maximal protective effect was seen at around 3–4 cups
each day. The findings were robust to excluding events
in the first 5 years. Drinkers of decaffeinated, instant and
ground coffee (including espresso) also had lower risks
of incident CLD, incident CLD or steatosis, death from
CLD and, to a lesser extent, HCC, with ground coffee
(including espresso) having the largest effect.
This study agrees with previous cohort studies that
generally report inverse associations between coffee
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Table 2 Baseline characteristics of the 494,585 participants in the UK Biobank cohort and distribution of incident chronic liver
disease, incident chronic liver disease or steatosis, death from chronic liver disease and incident hepatocellular carcinoma according
to coffee consumption
Coffee (cups/d) 0 Half 1 2 3 4 ≥5
N 109,767 35,876 99,179 92,886 60,479 41,515 54,883
Median age (years) at baseline (IQR) 56 (13) 57 (13) 59 (13) 59 (13) 58 (12) 58 (13) 57 (13)
Sex (% female) 58.3 55.3 57.2 54.3 52.4 50 47.5
Ethnicity (%)
White 89.7 92.7 93.8 95.7 96.8 97.4 97.6
Other ethnicity 9.9 7.0 5.9 4.0 2.9 2.2 2.0
Unknown 0.4 0.4 0.3 0.3 0.3 0.4 0.3
Median Townsend deprivation score −1.70 −2.15 −2.23 −2.32 −2.38 −2.35 −2.06
Alcohol frequency (%)
Never 14.4 6.9 6.4 5.3 5.1 5.5 7.7
Special occasions only 15.9 12.1 11.1 9.1 8.8 9.2 12.0
One to three times a month 12.6 12.7 11.0 9.9 9.8 10.1 11.8
Once or twice a week 24.9 26.6 27.0 26.1 25.3 25.8 25.4
Three or four times a week 17.6 23.2 24.0 25.8 26.3 25.8 22.3
Daily or almost daily 14.5 18.5 20.4 23.6 24.6 23.5 20.7
Unknown 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Mean weekly units (IQR) 11 (24.3) 15 (24.8) 15.2 (23.3) 17.5 (23.8) 18.2 (24.2) 18.8 (25.2) 17.5 (27.8)
Diabetes (%)
Yes 5.7 5.0 4.9 4.7 5.0 5.3 5.7
No 93.9 94.7 94.8 95.0 94.8 94.4 94.0
Unknown 0.4 0.4 0.3 0.2 0.2 0.3 0.3
Median BMI in kg/m2 (IQR) 26.8 (6.1) 26.4 (5.7) 26.3 (5.6) 26.5 (5.5) 26.8 (5.5) 27.2 (5.7) 27.5 (5.9)
Smoking (%)
Never 58.6 58.3 57.6 55.3 53.6 50.3 42.3
Previous 31.3 33.1 34.8 35.7 36.2 36.9 35.9
Current 9.7 8.2 7.3 8.7 9.9 12.4 21.3
Unknown 0.4 0.4 0.3 0.4 0.4 0.4 0.4
CLD cases (n)
Total (%) 927 (0.84) 281 (0.78) 707 (0.71) 651 (0.70) 380 (0.63) 267 (0.64) 387 (0.71)
First 5 years excluded (%) 449 (0.41) 134 (0.37) 329 (0.33) 320 (0.34) 185 (0.31) 122 (0.29) 213 (0.39)
CLD or steatosis cases (n)
Total (%) 1412 (1.29) 394 (1.10) 1063 (1.07) 965 (1.04) 564 (0.93) 400 (0.96) 641 (1.17)
First 5 years excluded (%) 724 (0.66) 198 (0.55) 521 (0.53) 497 (0.54) 289 (0.48) 197 (0.47) 357 (0.65)
HCC cases (n)
Total (%) 44 (0.04) 10 (0.03) 33 (0.03) 40 (0.04) 24 (0.04) 15 (0.04) 18 (0.03)
First 5 years excluded (%) 28 (0.03) 1 (< 0.01) 3 (< 0.01) 3 (< 0.01) 1 (< 0.01) 0 (0.00) 3 (0.01)
CLD deaths(n)
Total (%) 97 (0.09) 23 (0.06) 49 (0.05) 56 (0.06) 29 (0.05) 17 (0.04) 30 (0.05)
First 5 years excluded (%) 59 (0.05) 12 (0.03) 30 (0.03) 41 (0.04) 20 (0.03) 9 (0.02) 21 (0.04)
Abbreviations: N (number), BMI (body mass index), IQR (interquartile range), CLD (chronic liver disease), HCC (hepatocellular carcinoma)
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Table 3 Hazard ratios with 95% confidence intervals for associations of coffee consumption (all types) with incident chronic liver
disease, incident chronic liver disease or steatosis, death from chronic liver disease and incident hepatocellular carcinoma, as
calculated in unadjusted and multivariate analyses
HR1 (n = 494,585) HR2 (n = 494,585) HR3 (n = 486,251) HR4 (n = 408,835)
CLD
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.93 (0.81–1.06) 0.88 (0.77–1.01) 0.92 (0.80–1.06) 0.90 (0.76–1.05)
1 cup/d 0.84 (0.76–0.93) 0.78 (0.70–0.86) 0.84 (0.76–0.94) 0.87 (0.77–0.97)
2 cups/d 0.83 (0.75–0.92) 0.76 (0.69–0.84) 0.81 (0.73–0.90) 0.80 (0.71–0.90)
3 cups/d 0.74 (0.66–0.84) 0.68 (0.60–0.77) 0.70 (0.62–0.80) 0.73 (0.64–0.83)
4 cups/d 0.76 (0.66–0.87) 0.70 (0.61–0.80) 0.70 (0.60–0.80) 0.71 (0.61–0.82)
≥ 5 cups/d 0.84 (0.74–0.94) 0.79 (0.71–0.89) 0.70 (0.62–0.79) 0.72 (0.63–0.83)
Any amount 0.82 (0.76–0.88) 0.76 (0.71–0.82) 0.78 (0.72–0.84) 0.79 (0.72–0.86)
Any amount (excluding cases within first 5 years) 0.83 (0.74–0.92) 0.77 (0.69–0.86) 0.79 (0.70–0.88) 0.79 (0.70–0.90)
CLD or steatosis
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.85 (0.76–0.95) 0.82 (0.73–0.92) 0.90 (0.80–1.01) 0.87 (0.76–1.00)
1 cup/d 0.83 (0.77–0.90) 0.78 (0.72–0.85) 0.89 (0.81–0.96) 0.88 (0.80–0.97)
2 cups/d 0.81 (0.74–0.87) 0.75 (0.69–0.82) 0.84 (0.77–0.92) 0.81 (0.74–0.89)
3 cups/d 0.72 (0.66–0.80) 0.68 (0.61–0.75) 0.73 (0.66–0.81) 0.74 (0.66–0.83)
4 cups/d 0.75 (0.67–0.84) 0.70 (0.63–0.78) 0.71 (0.64–0.80) 0.71 (0.62–0.81)
≥ 5 cups/d 0.91 (0.83–1.00) 0.87 (0.80–0.96) 0.79 (0.71–0.87) 0.78 (0.70–0.87)
Any amount 0.81 (0.76–0.86) 0.77 (0.72–0.81) 0.82 (0.76–0.87) 0.80 (0.75–0.86)
Any amount (excluding cases within first 5 years) 0.81 (0.74–0.88) 0.77 (0.71–0.84) 0.81 (0.74–0.89) 0.79 (0.71–0.88)
HCC
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.69 (0.35–1.38) 0.63 (0.32–1.25) 0.63 (0.31–1.30) 0.51 (0.22–1.23)
1 cup/d 0.83 (0.53–1.30) 0.71 (0.45–1.12) 0.75 (0.47–1.21) 0.70 (0.41–1.19)
2 cups/d 1.07 (0.70–1.64) 0.90 (0.59–1.38) 0.91 (0.58–1.43) 1.03 (0.63–1.66)
3 cups/d 0.99 (0.60–1.62) 0.84 (0.51–1.37) 0.87 (0.52–1.44) 1.02 (0.60–1.74)
4 cups/d 0.90 (0.50–1.62) 0.77 (0.43–1.38) 0.76 (0.42–1.38) 0.74 (0.38–1.43)
≥ 5 cups/d 0.82 (0.47–1.42) 0.75 (0.43–1.29) 0.68 (0.39–1.19) 0.62 (0.33–1.18)
Any amount 0.91 (0.65–1.27) 0.78 (0.56–1.10) 0.79 (0.55–1.12) 0.80 (0.54–1.19)
Any amount (excluding cases within first 5 years) 0.83 (0.54–1.28) 0.71 (0.46–1.10) 0.73 (0.46–1.15) 0.74 (0.45–1.23)
Death from CLD
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.72 (0.46–1.14) 0.67 (0.42–1.06) 0.69 (0.43–1.10) 0.60 (0.36–1.02)
1 cup/d 0.56 (0.40–0.79) 0.51 (0.36–0.72) 0.54 (0.38–0.76) 0.55 (0.38–0.80)
2 cups/d 0.68 (0.49–0.95) 0.60 (0.43–0.84) 0.58 (0.41–0.81) 0.60 (0.42–0.87)
3 cups/d 0.54 (0.36–0.82) 0.47 (0.31–0.72) 0.45 (0.30–0.69) 0.49 (0.32–0.76)
4 cups/d 0.46 (0.28–0.78) 0.40 (0.24–0.67) 0.36 (0.21–0.61) 0.40 (0.23–0.69)
≥ 5 cups/d 0.62 (0.41–0.93) 0.54 (0.36–0.81) 0.40 (0.26–0.62) 0.39 (0.25–0.63)
Any amount 0.60 (0.47–0.76) 0.53 (0.42–0.68) 0.50 (0.39–0.64) 0.51 (0.39–0.67)
Any amount (excluding cases within first 5 years) 0.64 (0.47–0.87) 0.57 (0.42–0.77) 0.55 (0.40–0.76) 0.56 (0.39–0.78)
Abbreviations: CLD (chronic liver disease), HCC (hepatocellular carcinoma). 1unadjusted, 2adjusted for age and sex, 3as for 2 and additionally adjusted for
deprivation (Townsend score), smoking status (never, current or previous), diabetes (yes or no), ethnicity (white or other ethnicity), alcohol frequency (less than
weekly, once or twice a week, three or four times a week, and daily or almost daily) and BMI, 4as for 3 but adjusted for weekly alcohol units instead of
alcohol frequency
Kennedy et al. BMC Public Health          (2021) 21:970 Page 7 of 14
consumption and CLD outcomes, including deranged
liver enzymes [18], fibrosis [19], cirrhosis [7] and HCC
[6]. The protective effects of coffee have been observed
in different CLD aetiologies, such as ALD [7], NAFLD
[20] and chronic viral hepatitis [21]. Previous studies also
report a dose-response relationship up to 5 cups each day
[6] but there are limited data above this range. The inverse
association between coffee and HCC was weaker in this
study compared to previously reported estimates [6, 22,
23]. This was likely because of low power from a small
number of HCC cases and a shorter follow-up time com-
pared to other studies (e.g. 10.7 years compared to the
18–20 year follow-up times used by Setiawan et al. and Lai
et al. [9, 23]). There may also have been a lower propor-
tion of ground coffee drinkers, which may be more pro-
tective than other coffee types (see below).
The association between coffee consumption and
NAFLD was investigated in a recent Mendelian random-
isation study [24]. In that study, lifetime exposure to cof-
fee was estimated using genetic variants, which are fixed
before birth and not affected by confounders. While
there was an inverse association between coffee and
NAFLD, it did not reach statistical significance (odds ra-
tio 0.76; 95% CI 0.51–1.14). The lack of significance may
have been because the genetic variants used (four single
nucleotide polymorphisms) only explained a small pro-
portion of the variability of actual coffee consumption.
This study is the first, to our knowledge, to directly in-
vestigate the effect of different coffee types on CLD out-
comes in a single large cohort. There are few reports in
the literature about specific coffee types. A small study in
France found that filtered ground coffee but not espresso
was associated with a reduced risk of fibrosis in obese
women with NAFLD [25]. Indirect conclusions about
other coffee types can be inferred from studies in coun-
tries where drinking preferences differ. For example, in
Finland and Japan instant coffee is the most popular type,
and inverse associations with CLD outcomes have been
reported in both those countries [23, 26].
In the present study, decaffeinated coffee consumption
was associated with similar reductions in risks of inci-
dent CLD and incident CLD or steatosis to all coffee
types combined and a larger reduction in risk of death
from CLD (63% compared to 49%). A meta-analysis of
three studies reported inverse associations between de-
caffeinated coffee and HCC, though smaller in magni-
tude compared to caffeinated coffee [6]. A cohort study
in the United States reported a lower risk of death from
Fig. 2 A forest plot showing the associations between consumption of all coffee, decaffeinated coffee, instant coffee and ground coffee
(including espresso) with incident CLD, incident CLD or steatosis, incident HCC and death from CLD
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Table 4 Hazard ratios with 95% confidence intervals for associations of decaffeinated coffee consumption with incident chronic liver
disease, incident chronic liver disease or steatosis, death from chronic liver disease and incident hepatocellular carcinoma
HR1 HR2 HR3 HR4
CLD
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.85 (0.64–1.13) 0.83 (0.62–1.10) 0.90 (0.66–1.23) 0.85 (0.59–1.23)
1 cup/d 0.75 (0.63–0.91) 0.70 (0.58–0.85) 0.81 (0.67–0.98) 0.82 (0.66–1.02)
2 cups/d 0.78 (0.64–0.95) 0.72 (0.59–0.87) 0.81 (0.66–0.99) 0.83 (0.66–1.04)
3 cups/d 0.74 (0.58–0.94) 0.68 (0.53–0.87) 0.71 (0.55–0.91) 0.76 (0.58–1.01)
4 cups/d 0.80 (0.61–1.05) 0.74 (0.57–0.98) 0.81 (0.61–1.06) 0.85 (0.62–1.15)
≥ 5 cups/d 0.75 (0.58–0.95) 0.71 (0.56–0.91) 0.72 (0.56–0.92) 0.72 (0.54–0.97)
Any amount 0.77 (0.69–0.86) 0.72 (0.64–0.80) 0.79 (0.70–0.88) 0.80 (0.70–0.92)
Any amount (excluding cases within first 5 years) 0.83 (0.71–0.97) 0.78 (0.67–0.91) 0.85 (0.72–1.00) 0.86 (0.72–1.04)
CLD or steatosis
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.79 (0.62–1.01) 0.78 (0.61–0.99) 0.93 (0.72–1.19) 0.84 (0.62–1.15)
1 cup/d 0.75 (0.65–0.88) 0.71 (0.61–0.83) 0.82 (0.70–0.97) 0.81 (0.67–0.97)
2 cups/d 0.80 (0.68–0.93) 0.75 (0.64–0.87) 0.87 (0.74–1.02) 0.86 (0.72–1.03)
3 cups/d 0.75 (0.62–0.91) 0.70 (0.58–0.85) 0.77 (0.62–0.94) 0.83 (0.66–1.04)
4 cups/d 0.79 (0.64–0.99) 0.75 (0.60–0.93) 0.82 (0.66–1.03) 0.86 (0.67–1.11)
≥ 5 cups/d 0.94 (0.78–1.12) 0.90 (0.75–1.08) 0.90 (0.75–1.08) 0.91 (0.74–1.12)
Any amount 0.80 (0.73–0.87) 0.76 (0.69–0.83) 0.85 (0.77–0.93) 0.85 (0.76–0.95)
Any amount (excluding cases within first 5 years) 0.84 (0.74–0.94) 0.79 (0.70–0.90) 0.88 (0.77–1.00) 0.88 (0.76–1.01)
HCC
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d NA NA NA NA
1 cup/d 1.15 (0.56–2.36) 1.03 (0.50–2.12) 1.17 (0.57–2.44) 0.83 (0.32–2.14)
2 cups/d 1.14 (0.54–2.43) 0.99 (0.47–2.11) 1.08 (0.50–2.32) 1.23 (0.54–2.80)
3 cups/d 1.34 (0.57–3.14) 1.17 (0.50–2.75) 1.16 (0.49–2.76) 1.48 (0.61–3.55)
4 cups/d 1.23 (0.44–3.43) 1.08 (0.39–3.02) 1.07 (0.38–2.99) 1.01 (0.31–3.30)
≥ 5 cups/d 0.46 (0.11–1.91) 0.44 (0.11–1.80) 0.39 (0.09–1.61) 0.51 (0.12–2.15)
Any amount 1.08 (0.68–1.72) 0.96 (0.60–1.54) 0.99 (0.61–1.61) 1.01 (0.59–1.74)
Any amount (excluding cases within first 5 years) 1.17 (0.66–2.07) 1.04 (0.58–1.85) 1.10 (0.60–2.00) 1.07 (0.54–2.12)
Death from CLD
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.50 (0.16–1.56) 0.52 (0.16–1.63) 0.67 (0.21–2.12) 0.82 (0.26–2.62)
1 cup/d 0.29 (0.12–0.71) 0.29 (0.12–0.71) 0.37 (0.15–0.92) 0.18 (0.04–0.72)
2 cups/d 0.39 (0.17–0.89) 0.37 (0.16–0.85) 0.44 (0.19–1.02) 0.37 (0.13–1.01)
3 cups/d 0.30 (0.10–0.96) 0.29 (0.09–0.91) 0.32 (0.10–1.01) 0.39 (0.12–1.24)
4 cups/d 0.56 (0.21–1.52) 0.53 (0.19–1.43) 0.59 (0.21–1.60) 0.55 (0.17–1.75)
≥ 5 cups/d 0.21 (0.05–0.85) 0.20 (0.05–0.83) 0.20 (0.05–0.83) 0.27 (0.07–1.09)
Any amount 0.35 (0.22–0.56) 0.34 (0.22–0.54) 0.40 (0.25–0.64) 0.37 (0.22–0.62)
Any amount (excluding cases within first 5 years) 0.30 (0.16–0.56) 0.28 (0.15–0.53) 0.34 (0.18–0.63) 0.27 (0.13–0.58)
Abbreviations: CLD (chronic liver disease), HCC (hepatocellular carcinoma). 1unadjusted, 2adjusted for age and sex, 3as for 2 and additionally adjusted for
deprivation (Townsend score), smoking status (never, current or previous), diabetes (yes or no), ethnicity (white or other ethnicity), alcohol frequency (less than
weekly, once or twice a week, three or four times a week, and daily or almost daily) and BMI, 4as for 3 but adjusted for weekly alcohol units instead of
alcohol frequency
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Table 5 Hazard ratios with 95% confidence intervals for associations of instant coffee consumption with incident chronic liver
disease, incident chronic liver disease or steatosis, death from chronic liver disease and incident hepatocellular carcinoma
HR1 HR2 HR3 HR4
CLD
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 1.12 (0.95–1.32) 1.02 (0.87–1.21) 1.03 (0.87–1.23) 1.04 (0.86–1.27)
1 cup/d 0.94 (0.84–1.06) 0.84 (0.75–0.95) 0.91 (0.80–1.02) 0.95 (0.83–1.09)
2 cups/d 0.93 (0.83–1.05) 0.84 (0.75–0.95) 0.88 (0.78–0.99) 0.87 (0.76–1.00)
3 cups/d 0.81 (0.70–0.93) 0.73 (0.63–0.84) 0.75 (0.64–0.86) 0.79 (0.67–0.92)
4 cups/d 0.80 (0.68–0.94) 0.73 (0.62–0.86) 0.71 (0.60–0.84) 0.73 (0.61–0.88)
≥ 5 cups/d 0.88 (0.77–1.01) 0.84 (0.73–0.96) 0.71 (0.62–0.82) 0.74 (0.63–0.87)
Any amount 0.90 (0.83–0.98) 0.83 (0.76–0.89) 0.82 (0.76–0.90) 0.85 (0.77–0.93)
Any amount (excluding cases within first 5 years) 0.90 (0.80–1.01) 0.83 (0.74–0.93) 0.82 (0.73–0.93) 0.84 (0.73–0.96)
CLD or steatosis
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 1.01 (0.87–1.16) 0.94 (0.82–1.08) 0.98 (0.84–1.13) 1.00 (0.84–1.18)
1 cup/d 0.93 (0.84–1.02) 0.85 (0.78–0.94) 0.95 (0.86–1.05) 0.97 (0.87–1.08)
2 cups/d 0.90 (0.82–0.99) 0.83 (0.75–0.92) 0.90 (0.81–1.00) 0.88 (0.78–0.98)
3 cups/d 0.79 (0.70–0.88) 0.73 (0.65–0.82) 0.76 (0.67–0.86) 0.78 (0.68–0.89)
4 cups/d 0.78 (0.69–0.89) 0.73 (0.64–0.84) 0.73 (0.63–0.83) 0.72 (0.62–0.84)
≥ 5 cups/d 0.92 (0.82–1.02) 0.88 (0.79–0.98) 0.77 (0.68–0.86) 0.76 (0.67–0.87)
Any amount 0.89 (0.83–0.95) 0.83 (0.77–0.88) 0.85 (0.79–0.91) 0.85 (0.79–0.92)
Any amount (excluding cases within first 5 years) 0.88 (0.81–0.97) 0.83 (0.76–0.91) 0.84 (0.76–0.93) 0.84 (0.75–0.94)
HCC
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 1.16 (0.55–2.47) 0.96 (0.45–2.04) 0.88 (0.40–1.98) 0.61 (0.22–1.74)
1 cup/d 0.84 (0.48–1.47) 0.67 (0.38–1.17) 0.64 (0.35–1.16) 0.62 (0.32–1.20)
2 cups/d 1.44 (0.89–2.31) 1.15 (0.72–1.86) 1.10 (0.67–1.81) 1.26 (0.74–2.14)
3 cups/d 1.15 (0.65–2.03) 0.94 (0.53–1.66) 0.92 (0.51–1.65) 1.08 (0.58–2.00)
4 cups/d 0.88 (0.43–1.81) 0.74 (0.36–1.52) 0.70 (0.34–1.44) 0.67 (0.29–1.51)
≥ 5 cups/d 0.83 (0.44–1.57) 0.74 (0.39–1.40) 0.66 (0.34–1.26) 0.56 (0.26–1.21)
Any amount 1.06 (0.74–1.51) 0.87 (0.61–1.25) 0.82 (0.56–1.20) 0.83 (0.55–1.27)
Any amount (excluding cases within first 5 years) 0.94 (0.59–1.49) 0.77 (0.49–1.22) 0.74 (0.45–1.21) 0.75 (0.43–1.30)
Death from CLD
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.99 (0.57–1.71) 0.85 (0.50–1.47) 0.84 (0.47–1.47) 0.75 (0.40–1.40)
1 cup/d 0.85 (0.59–1.24) 0.74 (0.51–1.08) 0.76 (0.51–1.12) 0.82 (0.55–1.22)
2 cups/d 0.91 (0.63–1.32) 0.78 (0.54–1.13) 0.74 (0.51–1.10) 0.81 (0.54–1.20)
3 cups/d 0.71 (0.45–1.13) 0.61 (0.38–0.97) 0.58 (0.36–0.93) 0.62 (0.38–1.02)
4 cups/d 0.36 (0.17–0.73) 0.30 (0.15–0.62) 0.27 (0.13–0.56) 0.32 (0.16–0.67)
≥ 5 cups/d 0.56 (0.34–0.93) 0.48 (0.29–0.80) 0.38 (0.23–0.63) 0.34 (0.19–0.61)
Any amount 0.75 (0.58–0.97) 0.64 (0.49–0.83) 0.59 (0.45–0.77) 0.62 (0.47–0.83)
Any amount (excluding cases within first 5 years) 0.81 (0.59–1.13) 0.69 (0.50–0.96) 0.66 (0.47–0.93) 0.69 (0.48–0.99)
Abbreviations: CLD (chronic liver disease), HCC (hepatocellular carcinoma). 1unadjusted, 2adjusted for age and sex, 3as for 2 and additionally adjusted for
deprivation (Townsend score), smoking status (never, current or previous), diabetes (yes or no), ethnicity (white or other ethnicity), alcohol frequency (less than
weekly, once or twice a week, three or four times a week, and daily or almost daily) and BMI, 4as for 3 but adjusted for weekly alcohol units instead of
alcohol frequency
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Table 6 Hazard ratios with 95% confidence intervals for associations of ground coffee consumption (including espresso) with
incident chronic liver disease, incident chronic liver disease or steatosis, death from CLD and incident hepatocellular carcinoma
HR1 HR2 HR3 HR4
CLD
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.59 (0.44–0.78) 0.58 (0.43–0.78) 0.60 (0.44–0.82) 0.64 (0.46–0.88)
1 cup/d 0.69 (0.58–0.82) 0.67 (0.56–0.79) 0.69 (0.58–0.83) 0.74 (0.61–0.90)
2 cups/d 0.66 (0.55–0.79) 0.61 (0.51–0.74) 0.64 (0.53–0.77) 0.65 (0.53–0.79)
3 cups/d 0.59 (0.46–0.75) 0.55 (0.42–0.70) 0.55 (0.43–0.72) 0.55 (0.42–0.73)
4 cups/d 0.59 (0.43–0.83) 0.55 (0.39–0.76) 0.53 (0.37–0.74) 0.52 (0.36–0.75)
≥ 5 cups/d 0.69 (0.50–0.95) 0.65 (0.47–0.90) 0.56 (0.40–0.78) 0.61 (0.43–0.87)
Any amount 0.65 (0.58–0.72) 0.61 (0.55–0.68) 0.62 (0.55–0.70) 0.64 (0.57–0.73)
Any amount (excluding cases within first 5 years) 0.63 (0.54–0.74) 0.60 (0.51–0.70) 0.62 (0.52–0.74) 0.66 (0.55–0.79)
CLD or steatosis
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.54 (0.42–0.69) 0.53 (0.42–0.68) 0.58 (0.45–0.76) 0.61 (0.46–0.80)
1 cup/d 0.65 (0.57–0.75) 0.63 (0.55–0.73) 0.73 (0.63–0.85) 0.74 (0.63–0.87)
2 cups/d 0.62 (0.54–0.72) 0.59 (0.51–0.68) 0.66 (0.56–0.77) 0.65 (0.55–0.77)
3 cups/d 0.53 (0.42–0.65) 0.49 (0.40–0.61) 0.56 (0.45–0.70) 0.54 (0.43–0.68)
4 cups/d 0.58 (0.44–0.77) 0.55 (0.42–0.72) 0.55 (0.42–0.73) 0.54 (0.40–0.73)
≥ 5 cups/d 0.78 (0.61–0.99) 0.74 (0.58–0.95) 0.69 (0.54–0.89) 0.66 (0.50–0.87)
Any amount 0.62 (0.56–0.67) 0.59 (0.54–0.64) 0.65 (0.59–0.72) 0.64 (0.58–0.72)
Any amount (excluding cases within first 5 years) 0.59 (0.52–0.67) 0.57 (0.50–0.65) 0.63 (0.55–0.73) 0.62 (0.53–0.72)
HCC
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.51 (0.12–2.12) 0.51 (0.12–2.09) 0.55 (0.13–2.29) 0.67 (0.16–2.81)
1 cup/d 0.68 (0.31–1.51) 0.64 (0.29–1.42) 0.68 (0.30–1.55) 0.84 (0.37–1.93)
2 cups/d 0.40 (0.14–1.12) 0.35 (0.13–0.99) 0.28 (0.08–0.90) 0.35 (0.11–1.15)
3 cups/d 0.38 (0.09–1.55) 0.33 (0.08–1.35) 0.33 (0.08–1.36) 0.41 (0.10–1.72)
4 cups/d 0.70 (0.17–2.87) 0.59 (0.14–2.45) 0.54 (0.13–2.27) 0.65 (0.15–2.71)
≥ 5 cups/d 1.12 (0.35–3.60) 0.99 (0.31–3.20) 0.84 (0.26–2.73) 1.06 (0.32–3.48)
Any amount 0.57 (0.34–0.97) 0.52 (0.30–0.88) 0.50 (0.28–0.88) 0.62 (0.35–1.11)
Any amount (excluding cases within first 5 years) 0.49 (0.25–0.99) 0.44 (0.22–0.88) 0.51 (0.24–1.08) 0.60 (0.27–1.30)
Death from CLD
No coffee 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
0.5 cups/d 0.23 (0.06–0.95) 0.23 (0.06–0.92) 0.21 (0.05–0.86) 0.23 (0.06–0.96)
1 cup/d 0.26 (0.12–0.60) 0.25 (0.11–0.58) 0.22 (0.10–0.51) 0.27 (0.12–0.63)
2 cups/d 0.46 (0.24–0.88) 0.41 (0.22–0.80) 0.34 (0.17–0.65) 0.38 (0.19–0.75)
3 cups/d 0.26 (0.08–0.81) 0.23 (0.07–0.71) 0.17 (0.05–0.55) 0.22 (0.07–0.69)
4 cups/d 0.63 (0.23–1.71) 0.54 (0.20–1.47) 0.40 (0.15–1.09) 0.50 (0.18–1.36)
≥ 5 cups/d 1.35 (0.66–2.78) 1.15 (0.56–2.37) 0.70 (0.32–1.51) 0.85 (0.39–1.85)
Any amount 0.43 (0.29–0.63) 0.39 (0.26–0.58) 0.31 (0.21–0.47) 0.37 (0.24–0.56)
Any amount (excluding cases within first 5 years) 0.47 (0.29–0.76) 0.43 (0.26–0.70) 0.36 (0.22–0.61) 0.42 (0.25–0.71)
Abbreviations: CLD (chronic liver disease), HCC (hepatocellular carcinoma). 1unadjusted, 2adjusted for age and sex, 3as for 2 and additionally adjusted for
deprivation (Townsend score), smoking status (never, current or previous), diabetes (yes or no), ethnicity (white or other ethnicity), alcohol frequency (less than
weekly, once or twice a week, three or four times a week, and daily or almost daily) and BMI, 4as for 3 but adjusted for weekly alcohol units instead of
alcohol frequency
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CLD among drinkers of two cups of decaffeinated coffee
each day compared to none, even after adjustment for
caffeinated coffee intake [9]. The observation of a pro-
tective effect of decaffeinated coffee is highly relevant to
the development of a coffee-based intervention for pre-
venting CLD onset or progression. Caffeine intolerance
may limit increases in coffee consumption, and thus de-
caffeinated coffee may be a preferable alternative. Given
its well know safety profile and cheap cost, coffee has
potential as widely accessible lifestyle intervention, even
in low to middle-income countries.
Strengths of this study include the large cohort size,
small numbers of exclusions (~ 2% in the analysis ad-
justed for alcohol frequency), the wide range of baseline
data on key confounders with which to make adjust-
ments in multivariate analyses, and the detailed data on
type of coffee consumption.
A limitation is the observational cohort design, which
cannot infer causation. There was a single timepoint of
coffee consumption, and volumes and preferred types
may have changed over the follow-up period. Cup sizes
may also have varied. However, misclassification of cof-
fee consumption would have pushed the effect size to-
wards null and not explain our results. There was also
no data on ex-coffee drinkers, which may be relevant to
reverse causation, as is discussed below. In addition,
there may have been differences in chemical compos-
ition between coffees within the same type (e.g. due to
different processes for decaffeination).
The risk of confounding was reduced by making ad-
justments for baseline covariates, but these may have
been assessed inaccurately or changed during follow-up.
In relation to alcohol consumption, a key CLD risk fac-
tor, the assumptions used to convert drinks into units,
such as the volume and alcohol content of each bever-
age, may have been inaccurate. In addition, imputation
of alcohol units was not used for missing data. The HRs
adjusted for weekly units were similar to those adjusted
for alcohol consumption frequency. While there may
have been some residual confounding from alcohol, it is
unlikely that this alone is responsible for the findings of
this study.
Bias may have been introduced from incomplete ad-
justment for socio-economic status using Townsend
deprivation index scores rather than individual level so-
cioeconomic variables (e.g. education) [12]. This would
have exaggerated the effect sizes because deprivation
was associated with CLD and non-coffee drinkers were
more deprived than coffee drinkers.
There were small differences in proportions of ethnici-
ties in the non-coffee drinking reference group com-
pared to the coffee drinking groups. Prevalence and
aetiology of CLD is known to vary between ethnic
groups [27], and this would have introduced bias if not
fully accounted for by binary adjustment for white or
other ethnicity. The results were also not adjusted for
waist circumference, which may be related to metabolic
syndrome independently of BMI, or prediabetes. Other
CLD risk factors not adjusted for included chronic infec-
tion with hepatitis B or C, though prevalence of these
conditions was likely low in this UK volunteer cohort.
Some cases and non-cases may have been misclassified
because of inaccuracies in the coded data used to ascer-
tain outcomes. Participants with an associated ICD-10
code K76.0 in the absence of other additional codes
identifying CLD were assumed to have simple steatosis
rather than more established forms of NAFLD (e.g. non-
alcoholic steatohepatitis, which corresponds to K75.81).
While this assumption may have led to under-
ascertainment of CLD cases, the risk of bias was likely
small given the similar associations of all coffee types
with CLD and CLD or steatosis.
Reverse causation was addressed by excluding diag-
nosed CLD at baseline. The presence of undiagnosed
cases might have exaggerated the effect sizes if CLD re-
sulted in coffee intolerance, and it was not possible to
identify previous coffee drinkers in our non-coffee
drinker category. However, the protective effect of coffee
was robust to exclusion of CLD outcomes in the first
five years of follow-up, suggesting that any effect of re-
verse causation was small.
It was not possible to fully assess the effects of very high
levels of coffee consumption as the numbers of events in
these categories were low. The risk reduction for ≥5 cups
each day was generally smaller than for 3 or 4 cups each day,
though still protective compared to no coffee, indicating that
there is likely a level beyond which increasing coffee con-
sumption confers no further benefit. Dose-response meta-
analyses report protective effects up to around 5 cups each
day with increasing uncertainty thereafter [6, 7].
The results of this study may be limited by the demo-
graphics of the voluntary UK Biobank Cohort, who were
predominantly white and likely over-representative of
those from higher socio-economic groups. As such, the
findings may not generalise to populations with a very
different ethnic and socio-economic composition.
Confidence in the veracity of the observed inverse as-
sociations of coffee consumption with CLD outcomes is
increased by several factors. These include the magni-
tude and significance of the effect sizes and the presence
of a dose response. In addition, residual confounding
was likely to have led to underestimation of the effect
sizes given that the adjusted HRs were generally larger
in magnitude and significance than the unadjusted HRs,
indicating coffee drinkers had a greater overall burden of
known CLD risk factors.
There is biological plausibility of a protective effect of
coffee against CLD outcomes. Caffeine is a non-selective
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antagonist of the A2aA receptor, activation of which
stimulates collagen production by hepatic stellate cells,
the primary mediators of fibrosis [28, 29]. However, in
the present study as well as in previous studies [6] decaf-
feinated coffee was also protective. Alternative active in-
gredients in coffee may include chlorogenic acid,
kahweol and cafestol, which protect against liver fibrosis
in animal studies [30, 31]. Kahweol and cafestol are
present in highest concentrations in ground coffee,
which was most protective. Given the protective effects
of the different coffee types with varying composition,
there may be a complex relationship involving more
than one active ingredient.
Conclusions
This study provides evidence of a protective effect of all
types of coffee (including decaffeinated) against CLD
outcomes. These findings are significant given the pau-
city of effective preventative and treatment strategies for
CLD, especially in low to medium income countries,
where the burden of CLD is highest. Further work is
now needed to replicate these findings using more ro-
bust methods, including Mendelian randomisation with
a more powerful set of genetic variants to estimate cof-
fee consumption than available previously. Randomised
trials should then investigate the efficacy of a coffee-
based intervention in those at risk of CLD or its
complications.
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